These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22292378)

  • 21. [Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine].
    Wang X; Su X; Yu J; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2893-7. PubMed ID: 22292394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
    Kou Q; Zhao S; Feng G; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine].
    Wei X; Zhang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2874-6. PubMed ID: 22292389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine].
    Li Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Veterinary pharmacovigilance in the European context.
    Keck G
    Ann Ist Super Sanita; 1992; 28(4):425-8. PubMed ID: 1303032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Traditional Chinese medicine pharmacovigilance in signal detection: decision tree-based data classification.
    Wei JX; Wang J; Zhu YX; Sun J; Xu HM; Li M
    BMC Med Inform Decis Mak; 2018 Mar; 18(1):19. PubMed ID: 29523131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
    van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
    Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M; Vegni F; Reich L; Younus M
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
    Yu X; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Application of nested case-control study on safe evaluation of post-marketing traditional Chinese medicine injection].
    Xiao Y; Zhao Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2796-8. PubMed ID: 22292368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Process and key points of clinical literature evaluation of post-marketing traditional Chinese medicine].
    Liu H; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2848-50. PubMed ID: 22292382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Signal Detection of Adverse Drug Reaction of Amoxicillin Using the Korea Adverse Event Reporting System Database.
    Soukavong M; Kim J; Park K; Yang BR; Lee J; Jin XM; Park BJ
    J Korean Med Sci; 2016 Sep; 31(9):1355-61. PubMed ID: 27510377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
    Shang HC; Zhang BL; Li YP
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Basic requirements on post-marketing clinical re-evaluation of chinese medicine and phase IV clinical trials].
    Xie Y; Wang Y; Tian F; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2764-7. PubMed ID: 22292359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database.
    Shalviri G; Mohammad K; Majdzadeh R; Gholami K
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1136-40. PubMed ID: 17705214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing data mining methods on the VAERS database.
    Banks D; Woo EJ; Burwen DR; Perucci P; Braun MM; Ball R
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):601-9. PubMed ID: 15954077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics].
    Jiang J; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2811-2. PubMed ID: 22292372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.
    Hauben M; Reich L
    J Clin Pharmacol; 2005 Apr; 45(4):378-84. PubMed ID: 15778418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A computerized system for signal detection in spontaneous reporting system of Shanghai China.
    Ye X; Fu Z; Wang H; Du W; Wang R; Sun Y; Gao Q; He J
    Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):154-8. PubMed ID: 19115240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.